Chunk #60 — 5. Procedures for evaluating pharmacological treatments targeting alcohol abuse and dependence — 5.4. Relapse of ethanol drinking in the home-cage
intake and/or voluntary intake of ethanol solutions over baseline (prior to the deprivation period) levels when ethanol is reinstated following a period of alcohol deprivation (Sinclair and Senter, 1967). The aripiprazole study, mentioned above, also examined the drug’s effects on ethanol relapse drinking, following a 2 week deprivation period. Similar to the findings of the maintenance test, the 15 mg/kg dose of aripiprazole reduced ethanol drinking on the 4th and 5th test days of relapse in P, but not HAD1, rats (K.M. Franklin, personal communication). There is considerable evidence that the alcoholic population is heterogeneous in nature (Babor et al., 1992; Cloninger, 1987; Conrod et al., 2000; Epstein et al., 1995; Lesch and Walter, 1996; Prelipceanu and Mihailescu, 2005; Windle and Scheidt, 2004; Zucker, 1987). Therefore, this latter finding of an effect in P, but not HAD1, rats provides support for testing promising compounds in multiple selectively bred lines, which could serve as models for different subtypes of alcoholics (See Tables 2 through 4; also see Litten et al., 2012). The fact that the AA, P, HAD1, HAD2 and sP rat lines display different levels of an ADE under particular conditions and for different periods of time, indicates that these
